SP Industries, a designer and manufacturer of laboratory equipment, biological drug...
Despite a lofty premium of more than 50% of NPS Pharmaceuticals’ (NPS) unaffected share price,...
Johnson & Johnson has licensed a potential treatment for inflammatory bowel diseases from a...
Tekmira Pharmaceuticals Corporation and OnCore Biopharma announced today that they have agreed to merge to create a global HBV company focused on developing a curative regimen for hepatitis B patients by combining multiple therapeutic approaches.
This novel technology uses lipid-like counter-ion salts to improve the solubility of drugs in lipid-based liquid, semi-solid and multiparticulate formulations. This technology adds to Capsugel Dosage Form Solutions’ growing suite of bioavailability enhancement technologies and capabilities.
Biogen Idec announced today that it has agreed to acquire U.K.-based Convergence Pharmaceuticals, a clinical-stage biopharmaceutical company with a portfolio of ion channel-modulating product candidates for neuropathic pain.
The acquisition will expand Shire's portfolio of specialty drugs, medications for niche diseases and conditions that typically command much higher price tags than conventional medications. Shire's best-selling drugs currently include the attention deficit disorder drugs Vyvanse and Adderall XR.
Roche is taking a majority stake in U.S.-based Foundation Medicine in a deal worth $1.03 billion that the Swiss pharmaceutical company says will help it to develop new treatment options for cancer patients.
AmerisourceBergen and MWI Veterinary Supply, today announced that they have entered into a definitive merger agreement for AmerisourceBergen to acquire MWI Veterinary Supply (MWI), the leading animal health distribution company in the United States.
Aptuit has divested its aseptic clinical manufacturing site in Glasgow, UK to Albany Molecular Research, Inc., and has entered into a definitive agreement with AMRI to acquire the West Lafayette, Indiana solid-state chemistry business for a total consideration of $60 million.
Based in Seattle, Washington, Sharpe Mixers has served customers for the past 60 years and provides mixing solutions in the chemical, industrial and sanitary markets. Hayward Gordon intends to make significant investment in plant, equipment and people in Sharpe's Seattle plant to better serve customers in the global market.
Gilead Sciences to Acquire Phenex Pharmaceuticals' Non-Alcoholic Steatohepatitis and Other Liver Diseases ProgramJanuary 6, 2015 8:55 am | News | Comments
Gilead Sciences and Phenex Pharmaceuticals AG today announced the signing of a definitive agreement under which Gilead will acquire Phenex’s Farnesoid X Receptor program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis.
Pfizer has acquired a controlling interest in Redvax GmbH, a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. This transaction provides access to a preclinical human cytomegalovirus (CMV) vaccine candidate.
OncoGenex Pharmaceuticals has executed an initial agreement with Teva Pharmaceutical Industries to regain rights to custirsen, an investigational compound currently being evaluated in Phase 3 clinical development as a treatment for prostate and lung cancers.
Just over a week after saying it would sell its heartworm treatment for dogs at the request of federal regulators, Eli Lilly announced that it has completed its $5.4 billion acquisition of the animal health division belonging to Switzerland's Norvartis.
Roivant Neurosciences has entered into an agreement with GlaxoSmithKline for the acquisition of SB742457, a selective 5-HT6 receptor antagonist with the potential to improve cognition and function in multiple central nervous system disorders.
The Federal Trade Commission is requiring the sale of Eli Lilly's Sentinel heartworm products because the Novartis deal would reduce competition and lead to higher prices. Eli Lilly will sell Sentinel to French pharmaceutical company Virbac.
Roche has announced the acquisition of Bina Technologies, a privately held company based in Redwood City, California, USA. Bina provides a big data platform for centralized management and processing of next generation sequencing (NGS) data.
Sartorius, an international laboratory and pharmaceutical equipment provider, is selling its Industrial Technologies Division (Intec) to the Japanese Minebea Co., Ltd. (Minebea) and their partner, the Development Bank of Japan Inc.
Merck has acquired, through a subsidiary, OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology drug development. Through the acquisition, Merck has gained an investigational, novel oral BET inhibitor, OTX015, which is currently in Phase 1b studies for the treatment of hematological malignancies and advanced solid tumors.
A wave of corporate mega deal activity drove a significant uptick in M&A value in 2014, according to PwC US. As businesses aim to meet their growth ambitions and increase market share, PwC expects there will be more attractive opportunities for dealmakers to acquire, combine and align with strategic partners in 2015.
Walgreens announced that Greg Wasson, president and chief executive officer, has informed the company’s board of directors that he will retire shortly after the close of the second step of the Alliance Boots transaction, on which shareholders are scheduled to vote on Dec. 29, 2014.
Merck remains committed to its $8.4 billion acquisition of Cubist Pharmaceuticals even though a federal court invalidated most of the company's patents protecting its top-selling antibiotic just hours after the deal was announced this week.
The debt-financed acquisition of Cubist Pharmaceuticals by Merck for $9.5 billion is the latest in a string of large, debt-financed acquisitions that are stressing the credit profiles of US healthcare companies, according to Fitch Ratings.
Natrol has announced the completion of the sale of substantially all of the company’s assets to Aurobindo Pharma USA Inc., a manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, for a purchase price of $132.5M plus assumed liabilities.
Sigma-Aldrich Corporation stockholders voted to adopt the previously announced merger agreement providing for the acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany at a special meeting of stockholders.
Merck is buying Cubist Pharmaceuticals for $8.4 billion, illustrating a new emphasis on combating so-called "superbugs" that are drawing dire warnings from global health organizations.
Noble Life Sciences, a provider of preclinical drug development services, has announced the acquisition of Spring Valley Laboratories, a full service, GLP-compliant, preclinical contract research organization for the development of drugs, vaccines, and medical devices.
- Page 1